Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets
Open Access
- 27 April 2021
- journal article
- research article
- Published by American Society for Microbiology in mBio
- Vol. 12 (2)
- https://doi.org/10.1128/mbio.00230-21
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a causative agent of the CoV disease 2019 (COVID-19) pandemic, enters host cells via the interaction of its receptor-binding domain (RBD) of the spike protein with host angiotensin-converting enzyme 2 (ACE2). Therefore, the RBD is a promising vaccine target to induce protective immunity against SARS-CoV-2 infection. In this study, we report the development of an RBD protein-based vaccine candidate against SARS-CoV-2 using self-assembling Helicobacter pylori-bullfrog ferritin nanoparticles as an antigen delivery system. RBD-ferritin protein purified from mammalian cells efficiently assembled into 24-mer nanoparticles. Sixteen- to 20-month-old ferrets were vaccinated with RBD-ferritin nanoparticles (RBD nanoparticles) by intramuscular or intranasal inoculation. All vaccinated ferrets with RBD nanoparticles produced potent neutralizing antibodies against SARS-CoV-2. Strikingly, vaccinated ferrets demonstrated efficient protection from SARS-CoV-2 challenge, showing no fever, body weight loss, or clinical symptoms. Furthermore, vaccinated ferrets showed rapid clearance of infectious virus in nasal washes and lungs as well as of viral RNA in respiratory organs. This study demonstrates that spike RBD-nanoparticles are an effective protein vaccine candidate against SARS-CoV-2.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2020R1A5A2017476, NRF-2020R1A2C3008339)
- Korea Research Institute of Bioscience and Biotechnology (KGM9942011)
- HHS | National Institutes of Health (CA200422, CA251275, AI140705, AI140705S, AI140718, AI152190, AI116585, AI116585S, DE023926, DE027888, DE028521)
This publication has 65 references indexed in Scilit:
- Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infectionNanomedicine: Nanotechnology, Biology and Medicine, 2012
- Lack of Innate Interferon Responses during SARS Coronavirus Infection in a Vaccination and Reinfection Ferret ModelPLOS ONE, 2012
- Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccinesEmerging Microbes & Infections, 2012
- Protective immune responses in mice induced by intramuscular and intranasal immunization with aMycoplasma pneumoniaeP1C DNA vaccineCanadian Journal of Microbiology, 2012
- Innate Immunity Mediates Follicular Transport of Particulate but Not Soluble Protein AntigenThe Journal of Immunology, 2012
- Effects of Different Adjuvants in the Context of Intramuscular and Intranasal Routes on Humoral and Cellular Immune Responses Induced by Detergent-Split A/H3N2 Influenza Vaccines in MiceClinical and Vaccine Immunology, 2012
- Ferret Respiratory System: Clinical Anatomy, Physiology, and DiseaseVeterinary Clinics of North America: Exotic Animal Practice, 2011
- The Crystal Structure of Ferritin from Helicobacter pylori Reveals Unusual Conformational Changes for Iron UptakeJournal of Molecular Biology, 2009
- The SARS-CoV ferret model in an infection–challenge studyVirology, 2008
- Mucosal immunity and vaccinesNature Medicine, 2005